Q3 EPS Estimate for Applied Therapeutics Raised by Analyst

Key Points

• Analysts at Leerink Partners have raised their Q3 2025 earnings per share (EPS) estimate for Applied Therapeutics to ($0.14), up from ($0.16).
• The stock has a current price target of $1.50 set by the Royal Bank of Canada, and it holds an average rating of "Moderate Buy" with a price target of $6.10.
• Institutional ownership is strong, with 98.31% of shares currently owned by institutional investors, indicating significant confidence in the company's future.

Applied Therapeutics Inc. (NASDAQ:APLT - Free Report) - Investment analysts at Leerink Partnrs increased their Q3 2025 earnings per share (EPS) estimates for Applied Therapeutics in a note issued to investors on Monday, August 18th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings per share of ($0.14) for the quarter, up from their prior estimate of ($0.16). The consensus estimate for Applied Therapeutics' current full-year earnings is ($0.65) per share. Leerink Partnrs also issued estimates for Applied Therapeutics' Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.57) EPS, Q1 2026 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.04) EPS, Q4 2026 earnings at ($0.10) EPS, FY2026 earnings at ($0.42) EPS and FY2027 earnings at ($0.33) EPS.

A number of other brokerages have also commented on APLT. Royal Bank Of Canada reissued a "sector perform" rating and set a $1.50 price target on shares of Applied Therapeutics in a research note on Wednesday, May 14th. Wall Street Zen raised Applied Therapeutics to a "sell" rating in a research note on Saturday, July 26th. Three research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, Applied Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $6.10.

Applied Therapeutics Trading Up 3.2%

Shares of APLT stock opened at $0.4994 on Thursday. The business's 50-day moving average price is $0.41 and its 200-day moving average price is $0.44. Applied Therapeutics has a 12 month low of $0.2950 and a 12 month high of $10.6237. The firm has a market capitalization of $71.92 million, a price-to-earnings ratio of -1.11 and a beta of 1.97.

Applied Therapeutics (NASDAQ:APLT - Get Free Report) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.17) by $0.02.

Hedge Funds Weigh In On Applied Therapeutics

Hedge funds have recently made changes to their positions in the stock. Marshall Wace LLP raised its position in shares of Applied Therapeutics by 144.8% during the fourth quarter. Marshall Wace LLP now owns 1,307,381 shares of the company's stock worth $1,124,000 after acquiring an additional 773,377 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its holdings in Applied Therapeutics by 2,511.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 5,420,920 shares of the company's stock worth $4,642,000 after purchasing an additional 5,213,370 shares in the last quarter. Vestal Point Capital LP increased its holdings in Applied Therapeutics by 904.4% in the fourth quarter. Vestal Point Capital LP now owns 11,500,000 shares of the company's stock worth $9,846,000 after purchasing an additional 10,355,000 shares in the last quarter. Millennium Management LLC increased its holdings in Applied Therapeutics by 252.2% in the fourth quarter. Millennium Management LLC now owns 1,329,149 shares of the company's stock worth $1,138,000 after purchasing an additional 951,779 shares in the last quarter. Finally, Propel Bio Management LLC increased its holdings in Applied Therapeutics by 46.4% in the fourth quarter. Propel Bio Management LLC now owns 9,615,420 shares of the company's stock worth $8,233,000 after purchasing an additional 3,047,562 shares in the last quarter. 98.31% of the stock is currently owned by institutional investors.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.